No connection

Search Results

ANL vs TLSI

ANL
Adlai Nortye Ltd.
BEARISH
Price
$7.95
Market Cap
$293.4M
Sector
Healthcare
AI Confidence
85%
TLSI
TriSalus Life Sciences, Inc.
BEARISH
Price
$4.60
Market Cap
$282.5M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
ANL
--
TLSI
--
Forward P/E
ANL
-31.18
TLSI
-18.4
P/B Ratio
ANL
36.98
TLSI
-6.79
P/S Ratio
ANL
--
TLSI
6.26
EV/EBITDA
ANL
-21.02
TLSI
-11.25

Profitability

Gross Margin
ANL
0.0%
TLSI
84.57%
Operating Margin
ANL
0.0%
TLSI
-24.77%
Profit Margin
ANL
0.0%
TLSI
-86.88%
ROE
ANL
-138.98%
TLSI
--
ROA
ANL
-29.81%
TLSI
-56.8%

Growth

Revenue Growth
ANL
--
TLSI
59.8%
Earnings Growth
ANL
--
TLSI
--

Financial Health

Debt/Equity
ANL
5.63
TLSI
--
Current Ratio
ANL
1.02
TLSI
2.8
Quick Ratio
ANL
0.69
TLSI
2.35

Dividends

Dividend Yield
ANL
--
TLSI
--
Payout Ratio
ANL
0.0%
TLSI
0.0%

AI Verdict

ANL BEARISH

Adlai Nortye Ltd. (ANL) exhibits severe financial distress, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health—alongside a dangerously high Debt/Equity ratio of 5.63 and negative ROE of -138.98%. The company shows no profitability, with zero margins and negative earnings, while its Price/Book ratio of 36.98 suggests extreme overvaluation relative to book value. Despite a recent 1Y return of +247.2%, this surge appears speculative rather than fundamentals-driven, with no analyst consensus and no dividend or cash flow generation. The absence of key valuation metrics and the lack of sustainable growth signals make the current price unsustainable.

Strengths
Recent strong short-term price momentum (+247.2% 1Y, +345.4% 6M)
High analyst target price ($31.00) indicating potential upside expectation
Market cap ($0.29B) places it in a small-cap biotech niche with high volatility potential
Risks
Piotroski F-Score of 1/9 signals severe financial deterioration and poor operational efficiency
Negative ROE (-138.98%) and ROA (-29.81%) indicate deep losses and capital destruction
Debt/Equity ratio of 5.63 is extremely high, signaling significant leverage risk
TLSI BEARISH

TLSI exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -6.79, indicating negative shareholders' equity. While the company shows strong top-line revenue growth of 59.80% and high gross margins, these are offset by a devastating profit margin of -86.88% and consistent earnings misses. The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider selling by the CEO and officers suggests a high-risk speculative profile. Overall, the deterministic health indicators signal a high probability of further capital erosion or dilution.

Strengths
Strong YoY revenue growth of 59.80%
High gross margin of 84.57% indicating strong product pricing power
Healthy short-term liquidity with a current ratio of 2.80
Risks
Negative shareholders' equity (P/B of -6.79) indicating insolvency risk
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Extreme negative profit margins (-86.88%)

Compare Another Pair

ANL vs TLSI: Head-to-Head Comparison

This page compares Adlai Nortye Ltd. (ANL) and TriSalus Life Sciences, Inc. (TLSI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile